Skip to content
CNS Clinical Research

Los Angeles, California

CNS clinical trials in Los Angeles, CA

77 CNS studies are recruiting participants at sites in Los Angeles as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Los Angeles at a glance

  • 77 studies are recruiting at a site in Los Angeles.
  • By phase: Early Phase 1 (1), Phase 1/2 (7), Phase 2 (14), Phase 2/3 (1), Phase 3 (18), Phase 4 (4), No phase (22), Observational (10). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (40), industry (37).
  • By research area: Depression (28), Parkinson's Disease (15), Schizophrenia (10), Epilepsy (9), Migraine (6), ADHD (4), Bipolar Disorder (3), Multiple Sclerosis (2).
  • Most recent update to one of these records: November 13, 2026.

Depression studies recruiting in Los Angeles

Basic details from each study's public record (the 30 most recently updated of 77). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study sites
    CalNeuro Research Group · Lipov Medical Group
    Registry record
    NCT06793397 · updated
  2. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    LivaNova
    Study site
    Keck Hospital of USC
    Registry record
    NCT03887715 · updated
  3. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles · Los Angeles General Medical Center
    Registry record
    NCT06748222 · updated
  4. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  5. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  6. In-patient SCC TMS

    • No phase
    • Ages 18 to 65
    • All sexes
    Sponsor
    University of California, Los Angeles
    Study site
    UCLA TMS Service and Research Service
    Registry record
    NCT05645575 · updated
  7. Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

    • No phase
    • Ages 22 to 70
    • All sexes
    Sponsor
    Abbott Medical Devices
    Study sites
    UCLA Department of Psychiatry · USC University Hospital
    Registry record
    NCT06423430 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Los Angeles

  1. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    USC - The Memory and Aging Center (MAC) - Alzheimer Disease Research Center (ADRC)
    Registry record
    NCT06585787 · updated
  2. Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis

    • No phase
    • Ages 12 to 30
    • All sexes
    Sponsor
    University of California, San Diego
    Study site
    University of California, Los Angeles
    Registry record
    NCT07756567 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Los Angeles

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    NRC Research Institute
    Registry record
    NCT06951698 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Los Angeles, CA on ClinicalTrials.gov.

ADHD studies recruiting in Los Angeles

  1. The Myelin Disorders Biorepository Project

    • Observational
    • All ages
    • All sexes
    Sponsor
    Children's Hospital of Philadelphia
    Study site
    Children's Hospital of Los Angeles
    Registry record
    NCT03047369 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure

    • No phase
    • Ages 8 to 12
    • All sexes
    Sponsor
    University of California, Los Angeles
    Study site
    University of California Los Angeles Semel Institute Division of Child & Adolescent Psychiatry
    Registry record
    NCT06847165 · updated
  4. AWARE: Management of ADHD in Autism Spectrum Disorder

    • Phase 4
    • Ages 4 to 17
    • All sexes
    Sponsor
    Daniel Coury
    Study site
    Children's Hospital Los Angeles
    Registry record
    NCT05916339 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Los Angeles

  1. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA Hematology/Oncology - Santa Monica ( Site 6905)
    Registry record
    NCT06469944 · updated
  2. Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Boston Scientific Corporation
    Study site
    Cedars Sinai Medical Center
    Registry record
    NCT02071134 · updated
  3. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA Department of Medicine - Hematology & Oncology ( Site 0047)
    Registry record
    NCT06841354 · updated
  4. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    UCLA Jonsson Comprehensive Cancer Center ( Site 0135) · USC Norris Comprehensive Cancer Center ( Site 0205)
    Registry record
    NCT06623422 · updated
  5. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Keck School of Medicine of USC · UCLA Neurology Outpatient Clinic
    Registry record
    NCT07174310 · updated
  6. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    • Phase 3
    • Ages 45 to 75
    • All sexes
    Sponsor
    BlueRock Therapeutics
    Study site
    UCLA NeuroTranslational Research Center
    Registry record
    NCT06944522 · updated
  7. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    University of California, Los Angeles
    Registry record
    NCT06680830 · updated
  8. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
    Registry record
    NCT07432958 · updated
  9. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Epilepsy studies recruiting in Los Angeles

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Brain Science Research Institute
    Registry record
    NCT05667142 · updated
  2. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of California Los Angeles (UCLA)
    Registry record
    NCT05716100 · updated
  3. Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Neurona Therapeutics
    Study sites
    University of California Los Angeles · University of Southern California Keck Hospital
    Registry record
    NCT05135091 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Migraine studies recruiting in Los Angeles

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study sites
    Clinical Research Institute · Keck School of Medicine of USC
    Registry record
    NCT06972056 · updated
  2. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    CA Medical Clinic for Headache
    Registry record
    NCT07616128 · updated
  3. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Clinical Research Institute · Downtown L.A. Research Center, Inc.
    Registry record
    NCT07645924 · updated
  4. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Clinical Research Institute · Downtown L.A. Research Center, Inc.
    Registry record
    NCT07674654 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Ask about studies near Los Angeles

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call